Incyte Corporation (NASDAQ: INCY - Get Free Report) has received an average recommendation of "Hold" from the twenty-one brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. The average 12

Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.

Incyte's povorcitinib shows sustained 54-week efficacy in HS, with strong response rates and safety profile, reinforcing its potential.

Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two late-stage trials.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2026--Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting.

Diversified Trust Co. cut its stake in Incyte Corporation (NASDAQ: INCY) by 37.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,135 shares of the biopharmaceutical company's stock after selling 8,360 shares during the quarter. Diversified Trust Co.'s holdings in Incyte were

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Executive Leadership Appointments.

Incyte is proactively addressing Jakafi's 2028 patent cliff through robust pipeline diversification and strategic acquisitions. Jakafi delivered $3.09B in 2025 sales, up 11% YoY, underpinning strong operational performance and funding for R&D. Opzelura posted 33% YoY growth with $678M in 2025 sales, highlighting successful portfolio expansion.

JPMorgan Chase and Co. lessened its stake in Incyte Corporation (NASDAQ: INCY) by 46.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 447,720 shares of the biopharmaceutical company's stock after selling 384,394 shares during the period. JPMorgan Chase and Co. owned

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2026--Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting.